Allergic conjunctivitis therapeutics - pipeline assessment and market forecasts to 2018

Industry analysis specialist GlobalData estimates that the global allergic conjunctivitis therapeutics market was valued at $970 million in 2010, and expects it to grow at a compound annual growth rate (CAGR) of 14.3% over the next eight years, to reach $2.8 billion by 2018.

The increase in disease awareness is anticipated to lead to a growth in the diagnosed and treated population which will be further complemented by rising compliance due to the availability of a sufficient number of treatment options including branded, generics and (over-the-counter) products.

This increase in the treated patient population, the increasing uptake of medications and the rising compliance will be the primary drivers for the growth of the allergic conjunctivitis therapeutics market in the future. There are no major pipeline products which are expected to drive the market. The major late stage products in the allergic conjunctivitis therapeutics pipeline are modified pollen extracts which only cater to a niche population.
Photocopied